IBio
iBio, Inc. is a biotechnology company specializing in plant-based protein expression technologies for the development and manufacturing of vaccines and therapeutic proteins. The company offers contract development and manufacturing services to various collaborators and third-party customers in the United States. Its lead therapeutic candidate, IBIO-100, is in investigational new drug development for systemic scleroderma and idiopathic pulmonary fibrosis. iBio is also advancing multiple vaccine candidates, including IBIO-200 and IBIO-201 for preventing severe acute respiratory syndrome coronavirus 2, and IBIO-400 for classical swine fever. The company utilizes its proprietary iBioLaunch and iBioModulator platforms to enable rapid production of biologics, facilitating applications for both proprietary and biosimilar products. iBio operates in two segments: Biopharmaceuticals, which focuses on product candidates, and Bioprocessing activities, which encompasses various manufacturing services. Through collaborations with organizations like Planet Biotechnology and Texas A&M University, iBio enhances its capabilities in developing therapeutics for infectious diseases and other health challenges. The company is headquartered in New York, New York.
RubrYc Therapeutics
Acquisition in 2022
RubrYc Therapeutics is a biotechnology company based in San Carlos, California, founded in 2017. The company focuses on the integration of chemistry and computation to decode protein interfaces, facilitating the discovery and development of antibody-based drugs with specific epitope selectivity. By leveraging advancements in molecular library synthesis and computational methods, RubrYc aims to enhance the antibody discovery process. Their innovative approach allows for the identification of antibodies that bind to therapeutically relevant epitopes, thereby providing valuable insights into the design of therapeutic antibodies. This technology not only accelerates preclinical antibody discovery for biotherapeutic partners but also seeks to reduce the risks associated with traditional drug discovery methods.
RubrYc Therapeutics
Series A in 2021
RubrYc Therapeutics is a biotechnology company based in San Carlos, California, founded in 2017. The company focuses on the integration of chemistry and computation to decode protein interfaces, facilitating the discovery and development of antibody-based drugs with specific epitope selectivity. By leveraging advancements in molecular library synthesis and computational methods, RubrYc aims to enhance the antibody discovery process. Their innovative approach allows for the identification of antibodies that bind to therapeutically relevant epitopes, thereby providing valuable insights into the design of therapeutic antibodies. This technology not only accelerates preclinical antibody discovery for biotherapeutic partners but also seeks to reduce the risks associated with traditional drug discovery methods.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.